Technical Description
The present invention provides a novel polymeric hydrogel for treating melanoma cancer. It offers a drug loaded linear biopolymer-based hydrogel for drug delivery of therapeutic agents which is released in a sustained manner, thereby enhancing its bioavailability in targeted cancerous tissues.
Problems Addressed
- Adverse Side Effects
- Poor Drug Bioavailability
- Low Treatment Efficacy
- Less Target-Specific Action
- Resistance to Drugs
- Uncontrolled Drug Delivery
Tech Features
- Targeted Drug Delivery
- Enhanced Drug Bioavailability
- High Treatment Efficacy
- Sustained Drug Release
- Eco-Friendly Hydrogel
- Transdermal Drug Delivery
Target Audience
- Pharmaceutical Industry
- Drug Delivery Technology Sector
- Cancer Hospitals
- Oncology Research Institutions
- Government Agencies Funding Cancer Research
Tech ID: P27-1227 TRL 4 Patent Status: Granted Available For Exclusive and Non-exclusive License
